1.. Introduction {#S1}
================

Heart disease is the leading cause of morbidity and mortality worldwide \[[@R1]\]. In the United States, heart attack or acute myocardial infarction (AMI) has an annual incidence of about 805,000 cases with a death rate of 96.8 per 100,000 \[[@R2]\]. Though coronary artery disease (CAD) is the most common cause of AMI \[[@R3]\], infarction can happen without significant coronary artery stenosis. Myocardial infarction with nonobstructive coronary arteries (MINOCA) includes syndromes of the epicardium, microvasculature, and emerging concepts like myocardial necrosis due to oxygen supply-demand mismatch \[[@R4]\]. A systematic review of 27 clinical trials/AMI registries reports MINOCA prevalence of 6% of AMI cases \[[@R5]\].

Coronary embolism (CE) is a heterogenous cause of MINOCA that can be divided into direct, paradoxical, and iatrogenic \[[@R6]\]. Direct CE is when an embolism enters the coronary circulation, originating from systemic circulation or an intracardiac focus on the left side of the heart. Paradoxical CE enters coronary circulation after passing from venous circulation via a septal defect or patent foramen oval. Iatrogenic encompasses any emboli associated with a procedure, usually cardiothoracic surgery or percutaneous coronary intervention (PCI). There is overlap between the different categories and other organization schema have also been proposed.

In spite of early autopsy series identifying CE \[[@R7]\] and advancements in cardiovascular imaging, prevalence of CE has not yet been evaluated across multiple trials/registries. A single center, retrospective study of 1776 de novo AMI patients reports CE prevalence of 2.9% of AMI cases \[[@R8]\]. As it could represent almost half of MINOCA cases, CE should not be considered a rare entity. We here undertake the first scoping study of CE to understand risk factors, diagnosis, sources of emboli, management, and mortality.

2.. Methods {#S2}
===========

On July 23rd, 2019, a systematic search was conducted using Pubmed, Google Scholar, CINAHL, Cochrane CENTRAL and Web of Science databases. Studies listing the keywords "embolism, myocardial infarction" were used to identify cases of myocardial arrhythmias associated with marijuana use. The reference list of each report was reviewed for potential additional cases. All cases were reviewed in detail. Data reviewed included demographic data, cardiovascular (CV) risk factors, electrocardiography (EKG) findings, troponin levels, transthoracic echocardiography, electrophysiology study, urine drug screen findings, coronary angiogram and management when available.

3.. Results {#S3}
===========

3.1.. Demographics {#S4}
------------------

A total of 232 unique cases were identified in 190 publications ([Table 1](#T1){ref-type="table"}). Males comprised 55.2% of the cases reported and females comprised 44.8%. Overall age range was 4 months to 87 years with mean 50.2 ± 17.9 years and median 51 years; 57.3% of cases were younger than 55 years and 42.7% of cases were 55 years or older. Male age range was 4 months to 87 years with mean 49.6 ± 18.1 years and median 51 years. Female age was 12 to 87 years with mean 51.0 ± 17.9 years and median 51 years ([Table 2](#T2){ref-type="table"}).

3.2.. Cardiovascular Risk Factors {#S5}
---------------------------------

The most prevalent cardiovascular risk factors and comorbidities in the population were as follows: atrial fibrillation 17.2%, hypertension 16.8%, hyperlipidemia 15.9%, prosthetic heart valves 15.9%, chronic valvular disease not treated with valve replacement 15.9%, rheumatic heart disease 12.5%, diabetes 9.91%, obesity 9.05%, history of CAD 9.05%, cerebrovascular disease 9.05%, and smoking 8.62%. Comprehensive risk factors and comorbidities are listed in [Table 3](#T3){ref-type="table"}.

3.3.. Presentation {#S6}
------------------

Patients presented with chest pain 66.8%, fever 19.0%, sudden death 6.03%, hypotension 3.35%, shortness of breath 3.35%, stroke 0.862%, and without symptoms 0.431% ([Table 4](#T4){ref-type="table"}).

3.4.. ECG Findings {#S7}
------------------

In the 219 cases reporting ECG findings ([Table 5](#T5){ref-type="table"}), ST elevation was found in 43.8%, ST depression in 11.4%, unspecified "infarct changes" in 26.5%, atrial fibrillation in 14.2%, T wave changes in 10.5%, and Q waves 3.65%.

3.5.. Angiographic Findings {#S8}
---------------------------

A total of 173 cases included angiographic findings ([Table 6](#T6){ref-type="table"}). Occluded arteries were found in 95.4% of cases. Lesions were found in the left anterior descending artery 52.0%, left circumflex artery 17.3%, right main coronary artery 17.3%, left main coronary artery 9.83%, obtuse marginal artery 2.89%, posterolateral artery 2.31%, diagonal artery 1.73%, and intermediate artery 0.578%.

3.6.. Trans-thoracic Echocardiography {#S9}
-------------------------------------

Of the 94 cases reporting TTE, the most common findings were wall motion abnormalities in 47.9% of cases, valvular dysfunction in 29.8%, systolic dysfunction in 25.5%, valve masses or vegetations in 22.3%, intracardiac masses in 18.1%, and chamber enlargement in 11.7%. Normal studies were reported in 9.57% of cases; additional findings are listed in [Table 7](#T7){ref-type="table"}.

3.7.. Trans-esophageal Echocardiography {#S10}
---------------------------------------

Transesophageal echocardiograms were reported in 63 cases. The most common findings were valves masses or vegetations in 39.7% of cases, intracardiac masses in 33.3%, and valvular dysfunction in 25.4%. Other findings are listed in [Table 8](#T8){ref-type="table"}.

3.8.. Causes of Coronary Embolism {#S11}
---------------------------------

The reason for CE, as per the case authors, were endocarditis 22.8%, prosthetic heart valve complications 15.1%, thromboembolism 13.4%, atrial fibrillation 12.5%, iatrogenic 12.5%, non-thrombotic embolic sources (including solid tumors, bone marrow, and septic emboli) 9.91%, chronic valvular disease 8.62%, and rheumatic heart disease 6.47%. A comprehensive list of CE causes is listed in [Table 9](#T9){ref-type="table"}.

3.9.. Management {#S12}
----------------

The most common interventions performed were thrombectomy 31.0%, PCI 22.0% (stent placed in 31.4% of these cases), anticoagulation 14.7%, thrombolytic therapy 9.48%, and antibiotics/antifungals 8.19%. A comprehensive list of interventions is listed in [Table 10](#T10){ref-type="table"}.

3.10.. Mortality {#S13}
----------------

Death was reported in 35.7% of cases ([Table 11](#T11){ref-type="table"}), of which 34.9% occurred after no intervention was performed, 15.7% after anticoagulation, 12.0% after antibiotic/antifungal therapy alone were given, 6.02% after surgical intervention, 4.82% after aspiration thrombectomy, 3.61% after valve repair/replacement, and 2.41% after thrombolytic therapy. Recurrence of coronary embolism was reported in 7 cases, 3 of which resulted in death.

4.. Discussion {#S14}
==============

The average age in the study population was approximately 15 years younger for males and 20 years younger for females than expected for all causes of MI, with females also representing a smaller percentage in all age groups relative to men than expected for all causes of MI \[[@R9]\]. While younger age and skew towards male sex may be due to small sample size and known underdiagnosis of MI in females \[[@R10]\], these demographic data correlate with findings in larger reviews of MINOCA \[[@R5]\]. Whether there is a unique patient population for CE should be confirmed in future studies.

Risk factors for CE overlapped with those for MI due to CAD (MI-CAD), specifically hypertension, hyperlipidemia, diabetes, CAD, CVD, and smoking. History of atrial fibrillation (AF), which is more commonly associated with cerebrovascular disease (CVD), was present in 17.2% of patients. Given the risk of thrombus formation in the left atrium in AF and its proximity to the coronary aortic cusps, thromboembolic events can occur in a similar fashion in the coronary circulation as they do in CVD. CE may occur less frequently than CVD in this setting due to the fast rate of flow of blood across the coronary ostia, high resistance to flow of the smaller caliber coronary vessels as dictated by Poiseuille's Law, and the acute angle of the origin of the coronary arteries \[[@R11]\]. Interestingly, demand ischemia from AF with rapid ventricular response has also been proposed as a mechanism for MINOCA due to AF \[[@R12]\].

Additional risk factors in CE patients are chronic valvular disease with or without a history of rheumatic heart disease and prosthetic heart valves. Complications of chronic valvular disease and malfunctioning prosthetic valves usually include heart failure and/or pulmonary hypertension, rather than MI \[[@R13],[@R14],[@R15]\]. Abnormal blood flow and changes in left atrial volume caused by mitral valve disease, especially in AF, may cause thrombus formation \[[@R16],[@R17]\] thereby contributing to thromboembolic CE. Thrombosed prosthetic valves have the potential to cause thromboembolic events \[[@R18]\] and may cause CE this way.

Chest pain was the presenting complaint in 66.8% of CE cases, but it is not specific for ischemia and does not distinguish MI due to CE from MI-CAD \[[@R19]\]. Shortness of breath, found in 3.35% of patients, is also a classic symptom for MI-CAD. Fever, found in 19.0% of cases, is an unusual symptom of an underlying cardiac issue except in infective endocarditis (IE) and pericarditis \[[@R20]\]. In cases where CE was later determined to have been caused by IE, fever was the initial complaint 69.8% of the time. Stroke was the initial reason for hospitalization in 2 cases, reinforcing that CE can be caused by a similar mechanism as embolic CVD.

Diagnostic investigations included ECG in 94.4% of cases, angiography in 74.6%, TTE in 40.5%, and TEE in 27.2%. The most common ECG finding was ST-elevation, followed by "infarct changes" and AF. These reports did not provide enough data to draw conclusions about how CE presents on ECG versus MI-CAD. Vessel distribution, determined angiographically, followed a similar pattern to MI-CAD \[[@R21]\]. However, micro-emboli and advancement of CE into small caliber vessels may lead to infarction in territories of angiographically normal vessels, contributing to underdiagnosis \[[@R22],[@R23]\]. TTE identified the probable embolic source in 40.4% of cases when performed and TEE identified the probable source in 76.2%. TEE is 92% sensitive and 98% for detecting thrombi in the left atrial appendage, which is the most common area for thrombus formation \[[@R24],[@R25],[@R26]\]. TEE is 90% sensitive for native valve endocarditis and 85% sensitive for prosthetic and device-related endocarditis \[[@R27]\].

Causes of CE were varied, but primarily involved pathology of the aortic and mitral valves. Prevalence of endocarditis (22.8%) was high in this population despite less than 4% of patients having a known history of endocarditis, valve vegetations, and intravenous drug use. 44.4% of patients had conditions predisposing to IE, including chronic valvular disease, prosthetic valves, and rheumatic heart disease \[[@R28]\]. This association of CE and IE may be a useful step towards creating a predictive tool for CE, especially because the Duke criteria for predicting IE is well-validated \[[@R29]\]. Additionally, since the incidence of IE has increased over a 10-year period in the United States \[[@R30]\], it may become easier to assess prevalence of CE and the need for specific management strategies in IE patients.

Iatrogenic CE occurred most commonly in valve repair, valve replacement, and PCI at an overall rate equal to AF. Coronary catheterization is the best studied in this context, having been reported to cause CE with subtherapeutic heparinization or insufficient flushing of coagulated blood in the catheter, as well as incomplete aspiration of air \[[@R31],[@R32]\]. These procedures likely have unique risks for CE, warranting further investigation.

Nearly every case reviewed initially treated the patient for presumptive MI-CAD, with antiplatelet therapy, symptomatic treatment, and angiography playing a central role. Thrombectomy, particularly aspiration thrombectomy was the most frequently chosen intervention, followed by PCI with or without stent placement. Reason for using aspiration thrombectomy versus PCI were not explicitly states in these cases, though previous international guidelines recommend routine use of aspiration thrombectomy with primary PCI and in cases of increased risk factors or high thrombus burden \[[@R17]\]. There was no difference in mortality at 180-days and a slightly higher incidence of stroke for patients who underwent aspiration \[[@R33]\]. ln the present study, all patients who underwent PCI survived, while 4 deaths occurred after aspiration thrombectomy. The ability to pathological examine relatively intact aspiration specimens has enhanced current understanding of the causes of CE, in spite of its questionable survival benefits.

Anticoagulation was the most common medical therapy given, with 14.7% of patients receiving it in the hospital and 43.1% receiving it upon discharge. Thrombolytic therapy was also given, most often as the primary therapy \[[@R34]\], though its use is not well-studied and may even result in distalization of the thromboembolism to a smaller branch \[[@R35]\]. In the absence of clear guidelines, therapeutic approach to CE in patients of clinical presentation varies greatly. Reasons for not including other therapies including risk of stent infection in endocarditis \[[@R36]\], lack of evidence for thrombolytic therapy \[[@R37]\], and "free floating" emboli determined unlikely to respond to angioplasty \[[@R38]\].

Death occurred at a higher rate in cases where CE was not explicitly treated. Mortality was 93.5% in patients receiving no intervention or symptomatic treatment, 58.8% in patients treated with antibiotics or antifungals alone, and 48.0% in patients treated with anticoagulation alone. One study \[[@R8]\] showed CE MI patients had a significantly higher mortality rate (hazard ratio 3.82) and cardiac death rate (HR, 5.39; 95% CI, 2.38--10.6) than MI-CAD patients, which underscores the need for better understanding of CE.

5.. Conclusion {#S15}
==============

CE is an understudied cause of MI. The at-risk populations appear to be younger and more male than the general MI-CAD population and have unique risk factors in addition to those typically associated MI-CAD, including AF and valvular heart disease. While clinical presentation and ECG was indistinct from MI-CAD, TTE and TEE often demonstrated an embolic focus. When the clinical picture is considered alongside imaging, the most likely causes of CE were determined to be endocarditis with valvular involvement, malfunctioning or thrombosed prosthetic heart valves, intracardiac thrombi, and atrial fibrillation. There are no validated diagnostic algorithms for CE and as such it should be considered a possibility alongside the more traditional causes of MI, especially when the patient has known valve pathology or hemodynamically compromised valves on echocardiography. Definitive management strategies are challenging, in part due to the heterogeneity of causes of CE. The study shows that, in cases where the embolism itself was not directly addressed by thrombectomy, PCI, or thrombolysis, CE mortality was high.
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Cases of CE included in the study

   Serial Number   Year            Author             Reference
  --------------- ------ -------------------------- -------------
         1         1950       Moragues et al.        \[[@R39]\]
         2         1952        Walker et al.         \[[@R40]\]
         3         1952       Glushien et al.        \[[@R41]\]
         4         1954        Segall et al.         \[[@R42]\]
         5         1958         Gill et al.          \[[@R43]\]
         6         1958        Hoffman et al.        \[[@R44]\]
         7         1958      Lillington et al.       \[[@R45]\]
         8         1958       Kavanaugh et al.       \[[@R46]\]
         9         1959         Boas et al.          \[[@R47]\]
        10         1959         Gelpi et al.         \[[@R48]\]
        11         1958        Wegner et al.         \[[@R49]\]
        12         1960       Marietta et al.        \[[@R50]\]
        13         1960        Winters et al.        \[[@R51]\]
        14         1961        Menzies et al.        \[[@R52]\]
        15         1961        Oakley et al.         \[[@R53]\]
        16         1961       Miyahara et al.        \[[@R54]\]
        17         1962         Jerie et al.         \[[@R55]\]
        18         1962        Shanoff et al.        \[[@R56]\]
        19         1964        Rivera et al.         \[[@R57]\]
        20         1965         Liban et al.         \[[@R58]\]
        21         1965        Harris et al.         \[[@R59]\]
        22         1966         Watt et al.          \[[@R60]\]
        23         1967         Ritch et al.         \[[@R61]\]
        24         1968       Woo-Ming et al.        \[[@R62]\]
        25         1969       Tsuchiya et al.        \[[@R63]\]
        26         1969     Parameswaran et al.      \[[@R64]\]
        27         1969         Reddy et al.         \[[@R65]\]
        28         1969         Hall et al.          \[[@R66]\]
        29         1971       Benchimol et al.       \[[@R67]\]
        30         1971      Richardson et al.       \[[@R68]\]
        31         1974       Hartveit et al.        \[[@R69]\]
        32         1974        Schatz et al.         \[[@R70]\]
        33         1974         Attai et al.         \[[@R71]\]
        34         1976        Pfeifer et al.        \[[@R72]\]
        35         1977        Fayemi et al.         \[[@R73]\]
        36         1978        Bedetti et al.        \[[@R74]\]
        37         1978         Saenz et al.         \[[@R75]\]
        38         1979        Sridhar et al.        \[[@R76]\]
        39         1979        McHenry et al.        \[[@R77]\]
        40         1982          Lin et al.          \[[@R78]\]
        41         1984     Przybojewski et al.      \[[@R79]\]
        42         1984     Przybojewski et al.      \[[@R80]\]
        43         1985         Marx et al.          \[[@R81]\]
        44         1986         Ueda et al.          \[[@R82]\]
        45         1986        Presant et al.        \[[@R83]\]
        46         1987        Culver et al.         \[[@R84]\]
        47         1987        Maddoux et al.        \[[@R85]\]
        48         1987       Ackermann et al.       \[[@R86]\]
        49         1988       Mercereau et al.       \[[@R87]\]
        50         1988        Backer et al.         \[[@R88]\]
        51         1988       Jungbluth et al.       \[[@R89]\]
        52         1990      Vasiljevic et al.       \[[@R90]\]
        53         1991        Herzog et al.         \[[@R91]\]
        54         1992        Valente et al.        \[[@R92]\]
        55         1993         Bell et al.          \[[@R93]\]
        56         1995       Eckstein et al.        \[[@R94]\]
        57         1996        Haynes et al.         \[[@R95]\]
        58         1996        Abascal et al.        \[[@R96]\]
        59         1997         Iwama et al.         \[[@R97]\]
        60         1998         Quinn et al.         \[[@R98]\]
        61         1998       Matsumoto et al.       \[[@R99]\]
        62         1999         Lanza et al.         \[[@R100]\]
        63         2000        Perera et al.         \[[@R101]\]
        64         2000        Takada et al.         \[[@R102]\]
        65         2000          Tun et al.          \[[@R103]\]
        66         2000         Chan et al.          \[[@R104]\]
        67         2001    Mentzelopoulos et al.     \[[@R105]\]
        68         2002         Aslam et al.         \[[@R106]\]
        69         2002        Beldner et al.        \[[@R107]\]
        70         2002       Hernández et al.       \[[@R108]\]
        71         2002         Tobar et al.         \[[@R109]\]
        72         2003         Hung et al.          \[[@R110]\]
        73         2003         Ramos et al.         \[[@R111]\]
        74         2003      Meier-Ewert et al.      \[[@R112]\]
        75         2004        Kotooka et al.        \[[@R113]\]
        76         2004        Mahmood et al.        \[[@R114]\]
        77         2004         Haghi et al.         \[[@R115]\]
        78         2004        Eguchi et al.         \[[@R116]\]
        79         2004         Orban et al.         \[[@R117]\]
        80         2004       Petinaux et al.        \[[@R118]\]
        81         2005        Ozaydin et al.        \[[@R119]\]
        82         2005        Adachi et al.         \[[@R120]\]
        83         2014        Deepali et al.        \[[@R121]\]
        84         2005         Braun et al.         \[[@R122]\]
        85         2005        Taniike et al.        \[[@R123]\]
        86         2005        Pindado et al.        \[[@R124]\]
        87         2005      Kirkpatrick et al.      \[[@R125]\]
        88         2006      Vanoverbeke et al.      \[[@R126]\]
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###### 

Study population demographics (n = 232)

                     Total         Males       Females
  -------------- ------------- ------------- -----------
  Age (years)                                
  Mean (SD)       50.2 (17.9)   49.6 (18.1)   51 (17.7)
  Range            0.3 to 87     0.3 to 87    12 to 87
                                             
  Gender                                     
  Male n (%)      128 (55.2)                 
  Female n (%)    104 (44.8)                 

###### 

Historical cardiovascular risk factors (n = 232)

                                               N (%)
  ----------------------------------------- -----------
  Atrial fibrillation                        40 (17.2)
  Hypertension                               39 (16.8)
  Hyperlipidemia                             37 (15.9)
  Chronic Valvular Disease                   37 (15.9)
  Mitral valve                               21 (9.05)
  Aortic valve                               16 (6.90)
  Prosthetic heart valve                     37 (15.9)
  Mitral valve                               20 (8.62)
  Aortic valve                               11 (4.74)
  Aortic and mitral valves                   6 (2.59)
  Rheumatic heart disease                    29 (12.5)
  Valve unspecified                          18 (7.76)
  Mitral                                     9 (3.88)
  Aortic                                     2 (0.862)
  Diabetes                                   23 (9.91)
  Coronary artery disease                    21 (9.05)
  Cerebrovascular disease                    21 (9.05)
  Obesity                                    21 (9.05)
  Smoking                                    20 (8.62)
  End stage renal disease                    9 (3.88)
  Congestive heart failure                   7 (3.02)
  Deep vein thrombosis/pulmonary embolism    7 (3.02)
  Valve vegetations                          7 (3.02)
  Cardiomyopathy                             5 (2.16)
  Atrial septal defect                       3 (1.29)
  Alcohol abuse                              2 (0.862)
  Drug abuse                                 2 (0.862)
  Other arrhythmia                           2 (0.862)
  Aortic dissection                          2 (0.862)
  Obstructive sleep apnea                    2 (0.862)
  Anemia                                     2 (0.862)
  Patent foramen ovale                       2 (0.862)
  Pregnancy                                  2 (0.862)
  Systemic lupus erythematosus               2 (0.862)
  Intracardiac thrombus                      2 (0.862)
  Arteritis                                  1 (0.431)
  Aortic coarctation                         1 (0.431)
  Hypertrophic obstructive cardiomyopathy    1 (0.431)
  Hyperthyroidism                            1 (0.431)
  Liver disease                              1 (0.431)
  Ventricular septal defect                  1 (0.431)
  Endocarditis                               1 (0.431)
  Heart transplant                           1 (0.431)
  Tuberculosis                               1 (0.431)

###### 

Presenting complaints (n = 232)

                           n (%)
  --------------------- ------------
  Chest pain             157 (66.8)
  Fever                  44 (19.0)
  Sudden death           14 (6.03)
  Hypotension             8 (3.35)
  Shortness of breath     8 (3.35)
  Stroke                 2 (0.862)
  Asymptomatic           1 (0.431)

###### 

Infarct ECG findings (n = 219)

                                    n (%)
  ------------------------------ ------------
  ST changes                      114 (52.1)
  ST elevation                    96 (43.8)
  ST depression                   25 (11.4)
  ST change, unspecified           3 (1.37)
  Infarct changes, unspecified    58 (26.5)
  Atrial fibrillation             31 (14.2)
  T wave changes                  23 (10.5)
  T wave inversion                18 (8.22)
  T wave depression               2 (0.913)
  T wave change, unspecified      2 (0.913)
  Peaked T wave                   1 (0.457)
  Q waves                          8 (3.65)

###### 

Location of lesion on cardiac catheterization (n = 173)

                                       n (%)
  --------------------------------- -----------
  Left anterior descending artery    90 (52.0)
  Left circumflex artery             30 (17.3)
  Right main coronary artery         30 (17.3)
  Left main coronary artery          17 (9.83)
  Posterior descending artery        8 (4.62)
  No findings                        8 (4.62)
  Obtuse marginal artery             5 (2.89)
  Posterolateral artery              4 (2.31)
  Diagonal artery                    3 (1.73)
  Intermediate artery                1 (0.578)

###### 

Transthoracic echocardiography findings (n = 94)

                                 N (%)
  --------------------------- -----------
  Wall motion abnormalities    45 (47.9)
  Valvular dysfunction         28 (29.8)
  Mitral regurgitation         13 (13.8)
  Aortic regurgitation         9 (9.57)
  Tricuspid regurgitation      3 (3.19)
  Prosthetic valve             2 (2.13)
  Aortic stenosis              1 (1.06)
  Mitral valve prolapse        1 (1.06)
  Systolic dysfunction         24 (25.5)
  Valve mass or vegetation     21 (22.3)
  Intracardiac mass            17 (18.10
  LV                           8 (8.51)
  LA                           7 (7.45)
  RA                           2 (2.13)
  Chamber enlargement          11 (11.7)
  RV                           5 (5.32)
  LV                           3 (3.19)
  RA                           2 (2.13)
  LA                           1 (1.06)
  Normal                       9 (9.57)
  Pulmonary hypertension       4 (4.26)
  PFO                          3 (3.19)
  Cardiomyopathy               2 (2.13)
  Aortic dissection            1 (1.06)

###### 

Transesophageal echocardiography findings (n = 63)

                                 N (%)
  --------------------------- -----------
  Valve mass or vegetation     25 (39.7)
  Intracardiac mass            21 (33.3)
  LA                           17 (27.0)
  LV                           2 (3.17)
  RA                           2 (3.17)
  Valvular dysfunction         16 (25.4)
  Mitral regurgitation         9 (14.3)
  Prosthetic valve             3 (4.76)
  Aortic regurgitation         2 (3.17)
  Aortic stenosis              1 (1.59)
  Mitral valve prolapse        1 (1.59)
  Wall motion abnormalities    8 (12.7)
  Normal                       8 (12.7)
  PFO                          6 (9.52)
  Systolic dysfunction         6 (9.52)
  Aortic mass                  3 (4.76)
  Pulmonary embolism           1 (1.59)
  Gas bubbles                  1 (1.59)

###### 

Reason for thromboembolism (n = 232)

                                          n (%)
  ------------------------------------ -----------
  Endocarditis                          53 (22.8)
  Valve unspecified                     23 (9.91)
  Aortic valve                          11 (4.74)
  Mitral valve                          10 (4.31)
  Aortic and mitral valves              5 (2.16)
  Mitral and tricuspid valves           1 (0.431)
  Prosthetic heart valves               35 (15.1)
  Mitral valve only                     19 (8.20)
  Aortic valve only                     10 (4.31)
  Aortic and mitral valve               6 (2.59)
  Thrombus                              31 (13.4)
  Left ventricular thrombus             9 (3.88)
  DVT                                   9 (3.88)
  Arterial thrombus                     5 (2.16)
  Left atrial thrombus                  3 (1.29)
  Right atrial thrombus                 2 (0.862)
  Pulmonary artery thrombus             2 (0.862)
  Aortic cusp thrombus                  1 (0.431)
  Atrial fibrillation                   29 (12.5)
  Procedure/Iatrogenic                  29 (12.5)
  Valve repair/replacement              11 (4.74)
  PCI                                   6 (2.59)
  Ablation                              3 (1.29)
  Coronary angiography                  2 (0.862)
  ASD/VSD repair                        2 (0.862)
  Ascending aortic dissection repair    1 (0.431)
  AV cusp decalcification               1 (0.431)
  Hip replacement                       1 (0.431)
  Central venous nutrition injection    1 (0.431)
  Radial endarterectomy                 1 (0.431)
  Non-thrombotic embolic source         23 (9.91)
  Solid tumor                           20 (8.62)
  Septic                                2 (0.862)
  Bone marrow                           1 (0.431)
  Chronic valvular disease              20 (8.62)
  Mitral valve                          14 (6.03)
  Aortic valve                          6 (2.59)
  Rheumatic heart disease               15 (6.47)
  Mitral valve                          10 (4.31)
  Valve unspecified                     4 (1.72)
  Aortic valve                          1 (0.431)
  PFO                                   11 (4.74)
  Hypercoagulable state                 8 (3.35)
  Cardiomyopathy                        8 (3.35)
  ASD                                   5 (2.16)
  Unknown                               5 (2.16)
  MVP                                   2 (0.862)
  Other arrhythmia                      1 (0.431)
  VSD                                   1 (0.431)
  Double chamber LV                     1 (0.431)

###### 

Interventions (n = 232)

                                         n (%)
  ----------------------------------- -----------
  Thrombectomy                         72 (31.0)
  Aspiration thrombectomy              53 (22.8)
  Mechanical thrombectomy              11 (4.74)
  Surgical thrombectomy                8 (3.45)
  PCI                                  51 (22.0)
  Without stent placement              31 (13.4)
  With stent placement                 16 (6.90)
  Anticoagulation                      34 (14.7)
  Anticoagulation alone                25 (10.8)
  No intervention                      31 (13.4)
  Thrombolytic therapy                 22 (9.48)
  Antibiotics/antifungal               19 (8.19)
  Antibiotics/antifungal alone         17 (7.33)
  Excision of embolic source           18 (7.76)
  Valve surgery                        18 (7.76)
  Intervention not reported            18 (7.76)
  CABG                                 8 (3.45)
  Antiplatelet therapy alone           6 (2.58)
  PFO closure                          2 (0.862)
  Unspecified surgical intervention    2 (0.862)
  Heart transplant                     1 (0.431)
  RVAD                                 1 (0.431)
  Femoral vein clamp                   1 (0.431)

###### 

Mortality and intervention attempted (n = 83)

                                     n (%)
  ------------------------------- -----------
  No intervention                  29 (34.9)
  Anticoagulation                  13 (15.7)
  Anticoagulation alone            12 (14.5)
  Antibiotics/antifungals alone    10 (12.0)
  Surgical intervention            5 (6.02)
  Aspiration thrombectomy          4 (4.82)
  Valve surgery                    3 (3.61)
  Thrombolytic therapy             2 (2.41)
